EUCTR2013-003166-14-HR进行中（未招募）不适用
Multiple, fixed-dose, comparative efficacy and safety evaluation of RGB-02 and Neulasta® in patients undergoing chemotherapy treatment known to induce neutropenia.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Females = 18 and = 65 years of age.
- •2. Patients with invasive breast cancer (Stage IIB and III) appropriate for treatment with doxorubicin and docetaxel combination therapy in the neoadjuvant or adjuvant treatment setting.
- •3. ECOG performance status 0 or 1.
- •4. Chemotherapy naïve.
- •5. Adequate bone marrow function assessed during Screening, as indicated by:
- •a. ANC = 1.5 x10^9/L,
- •b. Platelet count = 100 x10^9/L, and
- •c. Hemoglobin > 8 g/dL.
- •6. Adequate renal and hepatic function assessed during Screening, as indicated by:
- •a. Estimated creatinine clearance = 50 mL/min calculated by the Cockcroft-Gault method,
- •b. Bilirubin, aspartate transaminase, alanine transaminase < 1.5 x upper limit of normal (ULN), and
- •c. Alkaline phosphatase < 2.5 x ULN.
- •7. Female patients with childbearing potential must have a negative urine pregnancy test within 3 days prior to the first dose of chemotherapy (Day 1 of Cycle 1) and must agree to use 2 reliable methods of contraception throughout the treatment period and for 3 months after discontinuation of treatment. The 2 methods of reliable contraception must include 1 highly effective method (intrauterine device, hormonal pills, injections or implants, tubal ligation, partner’s vasectomy), and 1 additional effective (barrier) method (diaphragm, cervical cap, male condom). True abstinence is acceptable when this is in line with the patient’s preferred and usual lifestyle. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
- •8. Written informed consent given before any study-related assessment is performed.
- •9. Patient is able and willing to co-operate with the requirements of the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 230
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1. Pregnant or breast-feeding women.
- •2. Co-existing active infection, or received systemic anti-infectives within 4 weeks prior to the first dose of chemotherapy (Day 1 of Cycle 1).
- •3. Significant cardiovascular disease defined as any history of documented or current congestive heart failure, current high-risk uncontrolled arrhythmias, current uncontrolled angina pectoris, current clinically significant valvular disease, current evidence of transmural infarction on ECG, or any other significant cardiovascular disease which in the Investigator’s judgment contraindicates the planned therapy (especially doxorubicin).
- •4. Any malignancy other than the current breast cancer within the last 5 years prior to randomization, with the exception of cervical carcinoma in situ, non-melanoma skin cancer, or superficial bladder tumors (Ta, Tis, or T1) that have been successfully and curatively treated with no evidence of recurrent or residual disease.
- •5. Radiation therapy within 4 weeks prior to randomization into this study.
- •6. Concurrent anti-cancer therapy, including endocrine therapy, immunotherapy and monoclonal antibody therapy, and any concurrent treatment with bisphosphonates.
- •7. Prior bone marrow or stem cell transplantation.
- •8. Sickle cell disease.
- •9. Other investigational drug administration within 4 weeks prior to the first dose of chemotherapy (Day 1 of Cycle 1).
- •10. Previous exposure to filgrastim, lenograstim, or pegfilgrastim.
- •11. Known allergy to any of the study drugs, including chemotherapy agents.
- •12. Contraindication for use of corticosteroids.
- •13. Systemic corticosteroid therapy within 2 weeks prior to randomization into this study. The use of topical or inhaled corticosteroids within 2 weeks prior to randomization may be allowed at the discretion of the Investigator.
- •14. Any co-existing medical condition that in the Investigator’s judgment will substantially increase the risk associated with the patient’s participation in the study.
研究者
相似试验
进行中（未招募）
不适用
A study designed to compare safety and efficacy of RGB-02 and Neulasta® in breast cancer patients receiving chemotherapyeutropenia and febrile neutropenia in patients being treated with cytotoxic chemotherapy for malignancy.MedDRA version: 14.1Level: PTClassification code 10029354Term: NeutropeniaSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 14.1Level: PTClassification code 10016288Term: Febrile neutropeniaSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2013-003166-14-HUGedeon Richter Plc.240
进行中（未招募）
不适用
A study designed to compare safety and efficacy of RGB-02 and Neulasta® in breast cancer patients receiving chemotherapyEUCTR2013-003166-14-BGGedeon Richter Plc.240
进行中（未招募）
不适用
A study designed to compare safety and efficacy of RGB-02 and Neulasta® in breast cancer patients receiving chemotherapyEUCTR2013-003166-14-CZGedeon Richter Plc.240
已完成
1 期
A single centre, double blind, randomised, parallel group, ascending single and multiple dose, safety and tolerability, pharmacokinetic and pharmacodynamic study of vaginal ointment in healthy women volunteersInfection - Sexually transmitted infectionsCervical neoplasiaCondyloma acuminatumACTRN12618000883213Zenith Technology Corp Ltd18
进行中（未招募）
不适用
An open, single and multiple dose, efficacy and safety Proof of Principle study of Liproca® Depot, a controlled release formulation of 2-hydroxyflutamide, injected into the prostate in patients with localized prostate cancer - Liproca® Depotprostate cancer (T1-T2), Gleason = 3+4 at the time of diagnose in prostate biopsyMedDRA version: 9.1Level: LLTClassification code 10007113Term: Cancer of prostateEUCTR2009-010079-25-FIIDDS AB